We then assessed the impact of age on outcome of select groups of patients harboring specific, recurring, AML-associated gene mutations, with focus on mutations for which approved targeted inhibitors exist, including mutations in the IDH1 and IDH2 genes, FLT3-ITD and FLT3-TKD. The gene discussed is IDH2; the disease is acute myeloid leukemia.